November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
16 citations
,
June 2009 in “Dermatologic Surgery” A 17-year-old boy with Temporal Triangular Alopecia successfully grew new hair after a hair restoration surgery using follicular unit transplantation.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
September 2024 in “Journal of the American Academy of Dermatology” Tight hairstyles under hijabs cause traction alopecia, worsened by prolonged wear.
1 citations
,
May 2017 in “The Journal of Internal Korean Medicine” Bojungikki-tang may help with hair regrowth during chemotherapy.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
5 citations
,
January 2015 in “Saudi journal for health sciences” Alopecia areata in Taif is common, mainly immune-related, and best treated with topical corticosteroids and vitamins.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
January 2025 in “Dermatologic Therapy” Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
Aloe vera hair tonic with 10% and 15% concentrations effectively promoted hair growth in male rats.
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
1 citations
,
January 2016 in “Dermatology Online Journal” Triangular temporal alopecia can occur in adults and should be correctly identified to prevent misdiagnosis.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
May 2020 in “Business Innovation & Entrepreneurship Journal” PASIKULA, a turmeric-based hair removal product, successfully sold well and boosted turmeric's economic value.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
1 citations
,
March 2024 in “PubMed” Tick bites can cause localized hair loss.
January 2024 in “International Journal of Medicine in Developing Countries” Most people in Alahsa, Saudi Arabia, have low awareness of thyroid disease symptoms and risk factors.
20 citations
,
January 2013 in “Annals of Dermatology” Topical minoxidil successfully treated temporal triangular alopecia.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.